New Research from the CWMH: No Increase in Major Malformations in Children with Prenatal Exposure to Olanzapine
No major malformations were associated with olanzapine exposure during the first trimester of pregnancy.
Essential Reads: Atypical Antipsychotics and Breastfeeding
Despite the increasing use of the newer “atypical” or second-generation antipsychotic agents to treat a spectrum of psychiatric disorders, we have relatively little data on the use of these newer atypical agents in breastfeeding women.
Atypical Antipsychotics and Breastfeeding
Women with bipolar disorder are at a higher risk for relapse during pregnancy and that the risk is even higher during the postpartum period. In addition, women with bipolar disorder are more vulnerable to postpartum [...]
New Research from the CWMH: Prenatal Exposure to Atypical Antipsychotics Does Not Increase Risk of Malformations
The use of the newer “atypical” or second-generation antipsychotic agents continues to increase. These medications are used to treat a spectrum of psychiatric disorders, including schizophrenia, bipolar disorder, major depression, PTSD and anxiety disorders. Although [...]
In Brief: Study Finds No Link Between Antipsychotics and Gestational Diabetes
Given the number of younger women using atypical antipsychotic medications, we need more accurate data regarding the reproductive safety of these medications. To better understand the link between antipsychotic medication and medical conditions associated with [...]
Meta-Analysis: Antipsychotics and Pregnancy Outcomes
Second-generation or “atypical” antipsychotics, such as olanzapine (Zyprexa), aripiprazole (Abilify), and risperidone (Risperdal), are used far more frequently than are the first-generation or “typical” antipsychotics, such as haloperidol (Haldol). This is largely because the newer [...]
Antipsychotics and Pregnancy Part 2: Preliminary Data from the MGH Pregnancy Registry
This is the second part of a two part series on the use of antipsychotic medications during pregnancy. Read Part 1 here, which reviews data from the Australian antipsychotic registry.
More Data on the Use of Atypical Antipsychotics During Pregnancy
Despite the use of the newer “atypical” antipsychotic agents to treat a spectrum of psychiatric disorders, including schizophrenia, bipolar disorder, major depression, PTSD and other anxiety disorders, three is relatively little data on the reproductive safety of these newer atypical agents.
Prevalence and Trends in the Use of Antipsychotic Medications during Pregnancy
Since their introduction in the 1990s, atypical (second-generation) antipsychotics have replaced typical (first generation) antipsychotics as the first-line treatment for schizophrenia and related psychotic disorders. These drugs are widely used by reproductive age women across many other disease states including bipolar disorder, major depression and anxiety disorders as either primary or adjunctive treatments.
Atypical Antipsychotic Medications: What Do We Know About Their Reproductive Safety?
Atypical antipsychotic medications are commonly used for the treatment of schizophrenia and bipolar disorder. Despite the increasing use of these medications in women of child-bearing age, there is still relatively little data regarding the reproductive safety and long-term neurodevelopmental effects of these medications. A recent study assessed the development of 76 infants with fetal exposure to atypical antipsychotics.